Argenx to Acquire Forte Biosciences in $2.2 Billion All-Cash Immunology Deal

European biotech leader Argenx expands its autoimmune pipeline by acquiring Dallas-based Forte Biosciences at $77 per share, representing a 41 percent premium.

Loading lens…